Literature DB >> 19786030

The beta3-adrenoceptor agonist GW427353 (Solabegron) decreases excitability of human enteric neurons via release of somatostatin.

Michael Schemann1, Nadia Hafsi, Klaus Michel, Olivia I Kober, Jutta Wollmann, Qin Li, Florian Zeller, Rupert Langer, Kevin Lee, Selim Cellek.   

Abstract

BACKGROUND & AIMS: beta3 Adrenoceptor (beta3-AR) is expressed on adipocytes and enteric neurons. GW427353 is a human selective beta3-AR agonist with visceral analgesic effects. Some of its effects may involve release of somatostatin (SST) and actions on enteric neurons. The aim of this study was to investigate the mode of action of GW427353 in human submucous neurons.
METHODS: Voltage sensitive dye imaging was used to record from human submucous neurons. SST release from human primary adipocytes was measured with enzyme-linked immunoabsorbent assay. Immunohistochemistry was used to detect adiponectin, beta3-AR, SST, SST2 receptors, tyrosine hydroxylase (TH), and protein gene product 9.5.
RESULTS: Confocal imaging showed cytoplasmic beta3-AR labeling in somata of submucous neurons and nerve varicosities. GW427353 had no direct postsynaptic actions but decreased fast synaptic input to submucous neurons. Tissue perfusion with GW427353 reduced nicotine-evoked neuronal spike frequency, an effect prevented by the beta3-AR antagonist SR-59230 and the SST2-receptor antagonist CYN154806 and mimicked by the SST2 receptor agonist octreotide. Adipocytes expressed adiponectin, beta3-AR, and SST. TH-positive fibers were in close proximity to adipocytes. Submucous neurons expressed SST2 receptors. Human primary adipocytes released SST in response to GW427353 in a concentration-dependent manner, an effect abolished by SR-59230.
CONCLUSIONS: Inhibitory action of GW427353 involves release of SST which stimulates inhibitory SST2 receptors on human submucous neurons. Adipocytes are a potential source for SST. beta3-AR activation may be a promising approach to reduce enteric neuron hyperexcitability. The action of GW427353 may be the neurophysiologic correlate of its beneficial effect in patients with irritable bowel syndrome. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19786030     DOI: 10.1053/j.gastro.2009.09.046

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

1.  Fast calcium and voltage-sensitive dye imaging in enteric neurones reveal calcium peaks associated with single action potential discharge.

Authors:  K Michel; M Michaelis; G Mazzuoli; K Mueller; P Vanden Berghe; M Schemann
Journal:  J Physiol       Date:  2011-10-31       Impact factor: 5.182

2.  Neuropharmacology of purinergic receptors in human submucous plexus: Involvement of P2X₁, P2X₂, P2X₃ channels, P2Y and A₃ metabotropic receptors in neurotransmission.

Authors:  A Liñán-Rico; J E Wunderlich; J T Enneking; D R Tso; I Grants; K C Williams; A Otey; K Michel; M Schemann; B Needleman; A Harzman; F L Christofi
Journal:  Neuropharmacology       Date:  2015-02-24       Impact factor: 5.250

Review 3.  Nutrient-induced changes in the phenotype and function of the enteric nervous system.

Authors:  Michel Neunlist; Michael Schemann
Journal:  J Physiol       Date:  2014-06-06       Impact factor: 5.182

Review 4.  Maternal separation as a model of brain-gut axis dysfunction.

Authors:  Siobhain M O'Mahony; Niall P Hyland; Timothy G Dinan; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2010-10-01       Impact factor: 4.530

Review 5.  Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.

Authors:  Theodor Bokic; Martin Storr; Rudolf Schicho
Journal:  Pharmacology       Date:  2015-07-01       Impact factor: 2.547

Review 6.  Translational neuropharmacology: the use of human isolated gastrointestinal tissues.

Authors:  G J Sanger; J Broad; V Kung; C H Knowles
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

7.  The treatment of neurogenic lower urinary tract dysfunction in persons with spinal cord injury: An open label, pilot study of anticholinergic agent vs. mirabegron to evaluate cognitive impact and efficacy.

Authors:  Michelle Trbovich; Terry Romo; Marsha Polk; Wouter Koek; Che Kelly; Sharon Stowe; Stephen Kraus; Dean Kellogg
Journal:  Spinal Cord Ser Cases       Date:  2021-06-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.